Literature DB >> 19933846

Impact of feedback phosphorylation and Raf heterodimerization on normal and mutant B-Raf signaling.

Daniel A Ritt1, Daniel M Monson, Suzanne I Specht, Deborah K Morrison.   

Abstract

The B-Raf kinase is a Ras pathway effector activated by mutation in numerous human cancers and certain developmental disorders. Here we report that normal and oncogenic B-Raf proteins are subject to a regulatory cycle of extracellular signal-regulated kinase (ERK)-dependent feedback phosphorylation, followed by PP2A- and Pin1-dependent dephosphorylation/recycling. We identify four S/TP sites of B-Raf phosphorylated by activated ERK and find that feedback phosphorylation of B-Raf inhibits binding to activated Ras and disrupts heterodimerization with C-Raf, which is dependent on the B-Raf pS729/14-3-3 binding site. Moreover, we find that events influencing Raf heterodimerization can alter the transforming potential of oncogenic B-Raf proteins possessing intermediate or impaired kinase activity but have no significant effect on proteins with high kinase activity, such as V600E B-Raf. Mutation of the feedback sites or overexpression of the Pin1 prolyl-isomerase, which facilitates B-Raf dephosphorylation/recycling, resulted in increased transformation, whereas mutation of the S729/14-3-3 binding site or expression of dominant negative Pin1 reduced transformation. Mutation of each feedback site caused increased transformation and correlated with enhanced heterodimerization and activation of C-Raf. Finally, we find that B-Raf and C-Raf proteins containing mutations identified in certain developmental disorders constitutively heterodimerize and that their signaling activity can also be modulated by feedback phosphorylation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19933846      PMCID: PMC2812223          DOI: 10.1128/MCB.00569-09

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  33 in total

Review 1.  Isotype-specific functions of Raf kinases.

Authors:  C Hagemann; U R Rapp
Journal:  Exp Cell Res       Date:  1999-11-25       Impact factor: 3.905

2.  B-Raf and Raf-1 are regulated by distinct autoregulatory mechanisms.

Authors:  Nancy H Tran; Xiaochong Wu; Jeffrey A Frost
Journal:  J Biol Chem       Date:  2005-02-14       Impact factor: 5.157

Review 3.  The prolyl isomerase PIN1: a pivotal new twist in phosphorylation signalling and disease.

Authors:  Kun Ping Lu; Xiao Zhen Zhou
Journal:  Nat Rev Mol Cell Biol       Date:  2007-11       Impact factor: 94.444

4.  Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization.

Authors:  Mathew J Garnett; Sareena Rana; Hugh Paterson; David Barford; Richard Marais
Journal:  Mol Cell       Date:  2005-12-22       Impact factor: 17.970

5.  Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases.

Authors:  R Marais; Y Light; H F Paterson; C S Mason; C J Marshall
Journal:  J Biol Chem       Date:  1997-02-14       Impact factor: 5.157

6.  Differential inhibition and posttranslational modification of protein phosphatase 1 and 2A in MCF7 cells treated with calyculin-A, okadaic acid, and tautomycin.

Authors:  B Favre; P Turowski; B A Hemmings
Journal:  J Biol Chem       Date:  1997-05-23       Impact factor: 5.157

7.  Phosphorylation by PKA of a site unique to B-Raf kinase.

Authors:  S König; B Guibert; C Morice; P Vernier; J V Barnier
Journal:  C R Acad Sci III       Date:  2001-08

8.  Differential regulation of B-raf isoforms by phosphorylation and autoinhibitory mechanisms.

Authors:  Isabelle Hmitou; Sabine Druillennec; Agathe Valluet; Carole Peyssonnaux; Alain Eychène
Journal:  Mol Cell Biol       Date:  2006-10-30       Impact factor: 4.272

9.  Identification of novel ERK-mediated feedback phosphorylation sites at the C-terminus of B-Raf.

Authors:  Tilman Brummer; Heike Naegele; Michael Reth; Yukiko Misawa
Journal:  Oncogene       Date:  2003-12-04       Impact factor: 9.867

10.  Prevalent overexpression of prolyl isomerase Pin1 in human cancers.

Authors:  Lere Bao; Amy Kimzey; Guido Sauter; Janusz M Sowadski; Kun Ping Lu; Da-Gong Wang
Journal:  Am J Pathol       Date:  2004-05       Impact factor: 4.307

View more
  105 in total

Review 1.  Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail.

Authors:  Gajanan S Inamdar; SubbaRao V Madhunapantula; Gavin P Robertson
Journal:  Biochem Pharmacol       Date:  2010-05-09       Impact factor: 5.858

Review 2.  Signal control through Raf: in sickness and in health.

Authors:  Jihan K Osborne; Elma Zaganjor; Melanie H Cobb
Journal:  Cell Res       Date:  2011-12-06       Impact factor: 25.617

Review 3.  Mechanistic principles of RAF kinase signaling.

Authors:  Christian M Udell; Thanashan Rajakulendran; Frank Sicheri; Marc Therrien
Journal:  Cell Mol Life Sci       Date:  2010-09-06       Impact factor: 9.261

Review 4.  MicroRNA-Based Therapeutic Strategies for Targeting Mutant and Wild Type RAS in Cancer.

Authors:  Sriganesh B Sharma; John Michael Ruppert
Journal:  Drug Dev Res       Date:  2015-08-18       Impact factor: 4.360

5.  The importance of Raf dimerization in cell signaling.

Authors:  Alyson K Freeman; Daniel A Ritt; Deborah K Morrison
Journal:  Small GTPases       Date:  2013-08-28

Review 6.  Extracellular-Regulated Kinases: Signaling From Ras to ERK Substrates to Control Biological Outcomes.

Authors:  Scott T Eblen
Journal:  Adv Cancer Res       Date:  2018-03-02       Impact factor: 6.242

Review 7.  Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.

Authors:  Matthew Dankner; April A N Rose; Shivshankari Rajkumar; Peter M Siegel; Ian R Watson
Journal:  Oncogene       Date:  2018-03-15       Impact factor: 9.867

8.  Phosphorylation of BRAF by AMPK impairs BRAF-KSR1 association and cell proliferation.

Authors:  Che-Hung Shen; Ping Yuan; Rolando Perez-Lorenzo; Yaqing Zhang; Sze Xian Lee; Yang Ou; John M Asara; Lewis C Cantley; Bin Zheng
Journal:  Mol Cell       Date:  2013-10-03       Impact factor: 17.970

9.  The prolyl isomerase Pin1 targets stem-loop binding protein (SLBP) to dissociate the SLBP-histone mRNA complex linking histone mRNA decay with SLBP ubiquitination.

Authors:  Nithya Krishnan; Tukiet T Lam; Andrew Fritz; Donald Rempinski; Kieran O'Loughlin; Hans Minderman; Ronald Berezney; William F Marzluff; Roopa Thapar
Journal:  Mol Cell Biol       Date:  2012-08-20       Impact factor: 4.272

Review 10.  Vemurafenib: the first drug approved for BRAF-mutant cancer.

Authors:  Gideon Bollag; James Tsai; Jiazhong Zhang; Chao Zhang; Prabha Ibrahim; Keith Nolop; Peter Hirth
Journal:  Nat Rev Drug Discov       Date:  2012-10-12       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.